BACKGROUND: Selenium is a potential chemopreventive agent against prostate cancer, whose chemoprotective effects are possibly mediated through the antioxidative properties of selenoenzymes. Interrelations with other antioxidative agents and oxidative stressors, such as smoking, are poorly understood. OBJECTIVES: The aims were to investigate the association between serum selenium and prostate cancer risk and to examine interactions with other antioxidants and tobacco use. DESIGN: A nested case-control study was performed within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Serum selenium in prospectively collected samples was compared between 724 incident prostate cancer case subjects and 879 control subjects, frequency-matched for age, time since initial screen, and year of blood draw. The men were followed for up to 8 y. RESULTS: Overall, serum selenium was not associated with prostate cancer risk (P for trend = 0.70); however, higher serum selenium was associated with lower risks in men reporting a high (more than the median: 28.0 IU/d) vitamin E intake [odds ratio (OR) for the highest compared with the lowest quartile of selenium: 0.58; 95% CI: 0.37, 0.91; P for trend = 0.05; P for interaction = 0.01] and in multivitamin users (OR for highest compared with the lowest quartile of selenium: 0.61; 95% CI: 0.36, 1.04; P for trend = 0.06; P for interaction = 0.05). Furthermore, among smokers, high serum selenium concentrations were related to reduced prostate cancer risk (OR for the highest compared with the lowest quartile of selenium: 0.65; 95% CI: 0.44, 0.97; P for trend = 0.09; P for interaction = 0.007). CONCLUSION: Greater prediagnostic serum selenium concentrations were not associated with prostate cancer risk in this large cohort, although greater concentrations were associated with reduced prostate cancer risks in men who reported a high intake of vitamin E, in multivitamin users, and in smokers.
BACKGROUND:Selenium is a potential chemopreventive agent against prostate cancer, whose chemoprotective effects are possibly mediated through the antioxidative properties of selenoenzymes. Interrelations with other antioxidative agents and oxidative stressors, such as smoking, are poorly understood. OBJECTIVES: The aims were to investigate the association between serum selenium and prostate cancer risk and to examine interactions with other antioxidants and tobacco use. DESIGN: A nested case-control study was performed within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Serum selenium in prospectively collected samples was compared between 724 incident prostate cancer case subjects and 879 control subjects, frequency-matched for age, time since initial screen, and year of blood draw. The men were followed for up to 8 y. RESULTS: Overall, serum selenium was not associated with prostate cancer risk (P for trend = 0.70); however, higher serum selenium was associated with lower risks in men reporting a high (more than the median: 28.0 IU/d) vitamin E intake [odds ratio (OR) for the highest compared with the lowest quartile of selenium: 0.58; 95% CI: 0.37, 0.91; P for trend = 0.05; P for interaction = 0.01] and in multivitamin users (OR for highest compared with the lowest quartile of selenium: 0.61; 95% CI: 0.36, 1.04; P for trend = 0.06; P for interaction = 0.05). Furthermore, among smokers, high serum selenium concentrations were related to reduced prostate cancer risk (OR for the highest compared with the lowest quartile of selenium: 0.65; 95% CI: 0.44, 0.97; P for trend = 0.09; P for interaction = 0.007). CONCLUSION: Greater prediagnostic serum selenium concentrations were not associated with prostate cancer risk in this large cohort, although greater concentrations were associated with reduced prostate cancer risks in men who reported a high intake of vitamin E, in multivitamin users, and in smokers.
Authors: J D Brooks; E J Metter; D W Chan; L J Sokoll; P Landis; W G Nelson; D Muller; R Andres; H B Carter Journal: J Urol Date: 2001-12 Impact factor: 7.450
Authors: Alkan Hacer Iynem; Ayşe Zeynep Alademir; Can Obek; Ali Riza Kural; Dildar Konukoğlu; Tülay Akçay Journal: Int Urol Nephrol Date: 2004 Impact factor: 2.370
Authors: P Knekt; A Aromaa; J Maatela; G Alfthan; R K Aaran; M Hakama; T Hakulinen; R Peto; L Teppo Journal: J Natl Cancer Inst Date: 1990-05-16 Impact factor: 13.506
Authors: Marco Vinceti; Gabriele Dennert; Catherine M Crespi; Marcel Zwahlen; Maree Brinkman; Maurice P A Zeegers; Markus Horneber; Roberto D'Amico; Cinzia Del Giovane Journal: Cochrane Database Syst Rev Date: 2014-03-30
Authors: Miyako Abe; Wanling Xie; Meredith M Regan; Irena B King; Meir J Stampfer; Philip W Kantoff; William K Oh; June M Chan Journal: BJU Int Date: 2011-01 Impact factor: 5.588
Authors: Gabriele Dennert; Marcel Zwahlen; Maree Brinkman; Marco Vinceti; Maurice P A Zeegers; Markus Horneber Journal: Cochrane Database Syst Rev Date: 2011-05-11
Authors: Stacy Loeb; Sarah B Peskoe; Corinne E Joshu; Wen-Yi Huang; Richard B Hayes; H Ballentine Carter; William B Isaacs; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-23 Impact factor: 4.254
Authors: Anatoly Samoylenko; Jubayer Al Hossain; Daniela Mennerich; Sakari Kellokumpu; Jukka Kalervo Hiltunen; Thomas Kietzmann Journal: Antioxid Redox Signal Date: 2013-04-15 Impact factor: 8.401
Authors: Yumie Takata; J Steven Morris; Irena B King; Alan R Kristal; Daniel W Lin; Ulrike Peters Journal: Prostate Date: 2009-11-01 Impact factor: 4.104